A total of 195 eyes of 195 patients with glaucoma who met the inclusion and exclusion criteria were included in the study. Of the 195 eyes, 14 eyes (7.2%) were excluded from further analysis because the OCT-A images were of poor quality or the MvD was not clearly contoured. Interobserver agreement in terms of MvD was excellent (к = 0.913; 95% confidence interval [CI] = 0.890–0.958).
Of 181 eyes, 58 (32.0%) had a single nonrecurrent DH and the remaining 63 (34.8%) had more than one DH during the follow-up period. Sixty eyes (33.1%) with no history of DH were presented as a control group. The demographic features of the participants with no DH, nonrecurrent DH, and recurrent DH are presented in
Table 1. The eyes with no DH, nonrecurrent DH, and recurrent DH had similar baseline characteristics, including age, baseline IOP, RNFL thickness, and MD of the VF. Mean follow-up periods were 5.83 ± 1.11 years in the no DH group, 5.71 ± 1.07 years in the non-recurrent DH group and 5.90 ± 1.20 years in the recurrent DH group (
P = 0.560). VF progression expressed as MD slope was more prominent with the recurrent DH group (−0.97 ± 2.20 dB/year) than the nonrecurrent DH group (−0.16 ± 0.47 dB/year,
P = 0.007) and central VF progression was significantly more frequent in the recurrent DH group (41.3%) than the nonrecurrent DH group (15.5%,
P = 0.002). Systemic factors, such as diabetes mellitus, systemic hypertension, and aspirin medication were not different among the three groups (
P = 0.521,
P = 0.163, and
P = 0.069, respectively); however, the presence of vascular symptoms was more frequent in the recurrent DH group (23.8%) than the nonrecurrent DH group (1.7%) and no DH group (1.7%,
P < 0.001). Presence of MvD was more frequent in the recurrent DH group (44.4%) than the nonrecurrent DH group (27.6%,
P = 0.041).
In the 58 eyes with nonrecurrent DH, the presence of MvD was further evaluated (
Table 2). There were 16 eyes of nonrecurrent DH with MvD (27.6%) and 42 eyes of nonrecurrent DH without MvD (72.4%). Nonrecurrent DH with MvD group had more prominent VF progression (MD slope, −0.45 ± 0.51 dB/year) and more frequent central VF progression (43.8%) than nonrecurrent DH without MvD (MD slope = −0.05 ± 0.40 dB/year,
P = 0.003 and central VF progression = 4.8%,
P = 0.001), even when nonrecurrent DH eyes with MvD had thicker baseline RNFL thickness (84.50 ± 8.50 mm) than nonrecurrent DH eyes without MvD (77.39 ± 11.51 mm,
P = 0.029).
Logistic regression analyses were performed to determine factors associated with central VF progression (
Table 3). Presence of DH (β = 2.72, 95% CI = 1.01–5.41,
P < 0.001), recurrent DH at different locations (β = 3.24, 95% CI = 2.41–5.13,
P < 0.001), presence of vascular symptoms (β = 5.54, 95% CI = 2.01–8.32,
P < 0.001) and MvD (β = 4.52, 95% CI = 2.34–7.77,
P < 0.001) were the factors significantly associated with central VF progression in the multivariate analysis.
The recurrent DH group was further classified according to the presence of MvD at the DH location (
Table 4). There were 28 eyes of recurrent DH with MvD (44.4%) and 35 eyes of recurrent DH without MvD (55.6%). Recurrent DH in MvD group experienced more frequent central VF progression (71.4%) than recurrent DH without MvD group (17.1%,
P < 0.001). Recurrent DH without MvD group had greater frequency to present with DH recurrence at different locations (42.9%) and more vascular symptoms (37.1%) than recurrent DH with MvD group (14.3%,
P = 0.013 and 7.1%,
P = 0.005, respectively).
Logistic regression analyses were performed to determine factors associated with recurrent DH (
Table 5). Presence of vascular symptoms (β = 7.81, 95% CI = 2.27–13.98,
P = 0.006) was the significant factor associated with the recurrent DH in the univariate analysis and also in the multivariate analysis (β = 7.83, 95% CI = 2.71–12.59,
P = 0.004) along with the presence of MvD at the DH location (β = 2.69, 95% CI = 1.19–6.04,
P = 0.018). In the regression analysis, to determine the factors associated with DH recurrence at different locations (
Table 6), the presence of vascular symptoms (β = 5.27, 95% CI = 2.83–8.24,
P = 0.002) and not accompanying MvD (β = 0.23, 95% CI = 0.06–0.88,
P = 0.033) were significant factors in the univariate analysis. Among these factors, the presence of vascular symptoms (β = 6.08, 95% CI = 2.17–10.37,
P = 0.004) was the factor significantly associated with the DH recurrence at different locations in the multivariate analysis. In the Kaplan-Meier analysis, the groups with recurrent DH demonstrated a higher cumulative probability of central VF progression compared to the single DH groups, irrespective of the presence of MvD. Within both the single and recurrent DH groups, eyes with MvD exhibited a higher cumulative probability of central VF progression (log rank test,
P < 0.001;
Fig. 1).
A representative example is shown in
Figure 2. A 51-year-old woman diagnosed with NTG in her left eye exhibited MvD at the inferotemporal location. She experienced an initial DH at the same inferotemporal location, followed by a recurrence at the same site. The DH recurred twice during the follow-up period. There was significant enlargement of localized RNFL defects and VF progression after 45 months (MD slope = −0.81 dB/year). A contrasting representative case is shown in
Figure 3, in which a 76-year-old man diagnosed with NTG in his left eye, without MvD, had an initial DH at the superotemporal location. Subsequently, there was a recurrence at different locations in the inferotemporal region. The DH recurred four times during the follow-up period, and he temporarily experienced DH recurrence at both the superotemporal and inferotemporal locations. The localized RNFL defect became more prominent, and VF progression was noted throughout 96 months (MD slope = −0.59 dB/year).